Haleon (LSE/NYSE: HLN) lifts H1 2026 EPS 12% and raises dividend
Haleon reported H1 2026 revenue of £5,602m, up 2.2% reported and 2.6% organically. Adjusted diluted EPS rose 12% to 10.3p, and adjusted operating profit increased to £1,364m with a 24.3% margin. Free cash flow was £769m and net debt £7.5bn. It raised the interim dividend 9% to 2.4p and kept FY 2026 guidance unchanged.
How this was made
The 30-second read
Why it matters
Adjusted profitability and cash generation improved, supporting shareholder returns, while reported earnings were hit by restructuring costs tied to an operating model change. FY 2026 organic growth and adjusted operating profit growth guidance were kept unchanged.
Market read
Traders can update near-term expectations for defensive consumer health earnings quality and capital return, but the unchanged FY guidance likely caps the surprise component.
What to watch
Reported diluted EPS fell 4.5% to 8.5p despite adjusted growth, so the market may scrutinize the durability of adjustments and the pace of gross margin expansion (50 to 80 bps medium-term goal).
Background
Haleon plc (Form 6-K) released its half-year results for the six months ended 30 June 2026, including dividend and buyback updates and FY 2026 outlook.
Ticker impact
Haleon reported H1 2026 adjusted diluted EPS up 12% to 10.3p and raised the interim dividend 9% to 2.4p, with FY 2026 guidance unchanged.
Near-term bias modestly positive, with focus on whether investors re-rate on adjusted margin and dividend/buyback sustainability versus restructuring drag.
The article provides multiple concrete datapoints (adjusted EPS, adjusted operating margin, free cash flow, dividend increase, buyback progress) plus an explicit statement that FY 2026 guidance is unchanged, which typically limits the magnitude of repricing.
Market effects
Consumer health and OTC peers may see read-across on margin resilience, productivity programs, and capital return cadence.
Limited direct regional spillover; primarily UK/Europe large-cap defensive consumer sentiment.
Moderate, as Haleon is a global consumer health name; could influence broader defensive staples positioning around earnings season.
Counterpoint
Investors may discount adjusted metrics if restructuring costs signal execution risk, and unchanged FY guidance suggests limited incremental upside.
Key entities
- companyHaleon plc
Reported H1 2026 revenue, adjusted EPS, margins, free cash flow, net debt, dividend increase, and buyback progress; maintained FY 2026 guidance.
